ClinicalTrials.gg
RecruitingNCT05346848DARIUSUpdated Oct 8, 2026

Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

A Phase 2 interventional study of Association of darolutamide and EBRT and Association of ADT and EBRT in Prostate Cancer, sponsored by Institut Bergonié. Recruiting at 10 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Institut Bergonié · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Prostatic Neoplasms by Institut Bergonié — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Institut Bergonié.

Started
2023
with 1 other
Phase 2
2 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Prostatic Neoplasms by Institut Bergonié, this one is one of 2 that started in 2023, is one of 2 in phase 2, and was the 8th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 10 studies in Prostatic Neoplasms by Institut Bergonié are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms by Institut Bergonié, or all of them as a file.
02

Study summary

Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.

Read the detailed description

Multicentric randomized non-comparative, open-label, phase II trial, based on signle-stage design, to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.

Patients satisfying eligibility criteria will be randomized according to 2 treatment modalities

  • Arm A (experimental arm): combination of external beam radiotherapy (EBRT) and 6 months darolutamide.
  • Arm B (standard arm): combination of external beam radiotherapy (EBRT) and 6 months ADT (androgen deprivation therapy)

Two patients randomized in arm A for one patient randomized in arm B.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • unfavorable intermdiate risk prostate cancer
  • androgen deprivation therapy
  • radiation therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18,
  2. Histological diagnosis of prostate cancer
  3. Cancer without loco-regional or distant (tumor assessment must comprise at least Pelvic MRI AND thoraco-abdomino-pelvic contrast-enhanced CT-Scan AND Bone Scintigraphy. (Note that additional assessment by PET-Scan is allowed as per investigator judgement),
  4. Unfavorable intermediate risk prostate cancer diagnosis defined by the NCCN Guidelines.

    One of the following criteria is sufficient to define an unfavorable intermediate risk prostate cancer:

    • Gleason = 7 (4+3)
    • ≥ 50% of thecore of need to be positive for adenocarcinoma

    If these criteria are not being identified, two or three of the following criteria are necessary to define unfavorable intermediate risk prostate cancer:

    • PSA value between 10-20 ng/ml
    • Gleason 7 (3+4) or 6
    • T2b (clinical or radiological) Note: patients with iT3a can be included only if gleason score is 6 and PSA less than 20 .
  5. Patients newly diagnosed with an unfavorable intermediate risk prostate cancer according to the protocol criteria or previously diagnosed with low risk (Gleason score \< 6, clinical stage \< T2a, and PSA\< 10) prostate cancer progressing to eligible risk disease according to the protocol criteria within 30 days before registration
  6. Patients must have a of at least 5 years,
  7. Performance status ≤ 2,
  8. Patients without to EBRT as per physician judgement,
  9. Patients with adequate organ function defined by all the following laboratory values
  10. Available archived paraffin-embedded tumor sample for research purpose,
  11. Patients with a social security in compliance with the french law,
  12. Voluntary signed and dated written prior to any study specific procedure,
  13. Men must agree to use an effective method of throughout the treatment period and for one week after discontinuation of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Stage T3b-T4 prostate cancer by clinical examination or radiologic evaluation,
  2. Patients with Gleason score ≥8,
  3. Patients with PSA >20 ng/ml,
  4. Presence of loco-regional or distant ,
  5. to MRI and to contrast-enhanced CT-scan,
  6. Hypogonadism or severe androgen deficiency as defined by screening serum testosterone less than 50 ng/dL or below the normal range for the institution.
  7. Previous prostate cancer treated by androgen deprivation, chemotherapy, surgery, or radiotherapy,
  8. Patients with previous orchiectomy
  9. Patients actively receiving or having received within 6 months prior enrollment any concurrent androgens, anti-androgens, estrogens, or progestational agents,
  10. Patients having received ketoconazole, finasteride or dutasteride within 30 days of inclusion,
  11. Previous and current other than prostate cancer within the last 5 years with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, acute lymphoblastic leukemia, non-muscle invasive bladder cancer,
  12. Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection),
  13. History of cerebrovascular accident (within the last 6 months)
  14. Impaired cardiac function as defined in the Protocol
  15. Uncontrolled hypertension
  16. Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of study drug,
  17. Major surgery within 4 weeks prior enrolment except pelvic lymph-nodes dissection,
  18. Known to any involved study drug or of its formulation components, to natural gonadotrophin releasing hormone or its analogues
  19. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption syndrome
  20. Men who are not using an effective method of as previously described
  21. Use of herbal or alternative remedies that may affect hormonal status such as Prostasol or PC-SPES,
  22. History of non-compliance to medical regimens or inability to grant consent,
  23. Patient unable to follow and comply with the study procedures because of any geographical, social or psychpsychological reasons,
  24. Individuals under judicial protection or deprived of liberty.
  25. Inability to swallow or to give subcutaneous or intramuscular injections.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Experimental Arm A: combination of radiotherapy and darolutamide

    Patients with unfavorable intermediate risk prostate cancer will be treated with darolutamide for a maximum of 6 months combined with external beam radiotherapy

    Drug: Association of darolutamide and EBRT

  • Other
    Standard Arm B: combination of radiotherapy and androgen deprivation therapy

    Patients with unfavorable intermediate risk prostate cancer will be treated with androgen deprivation therapy (ADT) as per market authorization combined with external beam radiotherapy

    Drug: Association of ADT and EBRT

Interventions

  • DrugAssociation of darolutamide and EBRT

    Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1. \- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules: * 78 Gy with classical 2 Gy/fractions, 5 days/7 * Or 60 Gy with 3 Gy/fractions, 5 days/7 * Use of IMRT and IGRT is mandatory * Clinical Target Volume Definition according to GETUG Guidelines * Organ at risk dose constraints according to RECORAD

  • DrugAssociation of ADT and EBRT

    Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on: * Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months, * Either LH-RH antagonist given monthly for 6 months External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions: * 78 Gy with classical 2 Gy/fractions, 5 days/7 * Or 60 Gy with 3 Gy/fractions, 5 days/7 * Use of IMRT and IGRT is mandatory * Clinical Target Volume Definition according to GETUG Guidelines * Organ at risk dose constraints according to RECORAD

06

What researchers measure

Primary outcomes

  1. Assessment of efficacy in terms of 6-month biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 6 months after randomization

Secondary outcomes

  1. Assessment of efficacy in terms of biological response at the end of darolutamide or ADT

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: An expected average of 6 months

  2. 2-month biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 2 months after randomization

  3. 3-month biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 3 months after the end of radiotherapy

  4. 6-month biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 6 months after the end of radiotherapy

  5. 9-month biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 9 months after the end of radiotherapy

  6. 2-year biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 2 years after randomization

  7. 3-year biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 3 years after randomization

  8. 5-year biological response

    Biological response is defined as a PSA concentration \<=0.1ng/mL according to Phoenix's criteria

    Time frame: 5 years after randomization

  9. 2-year biochemical progression-free survival (bPFS)

    Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first.

    Time frame: 2 years

  10. 3-year biochemical progression-free survival (bPFS)

    Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first.

    Time frame: 3 years

  11. 5-year biochemical progression-free survival (bPFS)

    Biochemical progression-free survival is defined as the delay between the date of randomization and the date of biochemical disease progression or death, whichever comes first.

    Time frame: 5 years

  12. 2-year metastasis free survival (MFS)

    Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy)

    Time frame: 2 years

  13. 3-year metastasis free survival (MFS)

    Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy)

    Time frame: 3 years

  14. 5-year metastasis free survival (MFS)

    Metastasis free survival is defined as the delay between the date of randomization and the date of metastasis diagnosis (imaging and/or biopsy)

    Time frame: 5 years

  15. 2-year disease free survival (DFS)

    Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause)

    Time frame: 2 years

  16. 3-year disease free survival (DFS)

    Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause)

    Time frame: 3 years

  17. 5-year disease free survival (DFS)

    Disease free survival is defined as the delay between the date of randomization and the first of the following events: biological PSA progression defined as level higher than PSA nadir + 2ng/mL according to Phoenix's criteria ; progression (local, regional, distant) or death (any cause)

    Time frame: 5 years

  18. 2-year prostate cancer-specific survival (PCSS)

    Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death

    Time frame: 2 years

  19. 3-year prostate cancer-specific survival (PCSS)

    Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death

    Time frame: 3 years

  20. 5-year prostate cancer-specific survival (PCSS)

    Prostate cancer-specific Survival is defined as the delay between the date of randomization and the date of prostate cancer-related death

    Time frame: 5 years

  21. 2-year overall survival (OS)

    Overall survival is defined as the delay between the date of randomization and the date of death (all cause).

    Time frame: 2 years

  22. 3-year overall survival (OS)

    Overall survival is defined as the delay between the date of randomization and the date of death (all cause).

    Time frame: 3 years

  23. 5-year overall survival (OS)

    Overall survival is defined as the delay between the date of randomization and the date of death (all cause).

    Time frame: 5 years

  24. Time to testosterone recovery

    Time to testosterone recovery defined as the time from randomization to the time when serum of total testosterone level increases to above the lower limit of the normal range.

    Time frame: An expected average of 6 months

  25. Acute safety profile independently for each treatment strategy

    Toxicity graded using the Common Terminology Criteria for Adverse Events version 5

    Time frame: 3 months

  26. Late 2-year safety profile independently for each treatment strategy

    Toxicity graded using the Common Terminology Criteria for Adverse Events version 5

    Time frame: 2 years

  27. Late 3-year safety profile independently for each treatment strategy

    Toxicity graded using the Common Terminology Criteria for Adverse Events version 5

    Time frame: 3 years

  28. Late 5-year safety profile independently for each treatment strategy

    Toxicity graded using the Common Terminology Criteria for Adverse Events version 5

    Time frame: 5 years

  29. Assessment of quality of life

    Quality of life will be assessed as per the EORTC QLQ-C30 questionnaire and prostate cancer module PR-25

    Time frame: Throughout the follow-up period, an expected average of 5 years

  30. Assessment of erectile dysfunction

    Erectile dysfunction will be assessed as per IIEF5

    Time frame: Throughout the follow-up period, an expected average of 5 years

  31. Assessment of symptoms of benign prostatic hyperplasia

    Symptoms of benign prostatic hyperplasia will be assessed as per IPSS

    Time frame: Throughout the follow-up period, an expected average of 5 years

07

Study locations

1 of 10 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 46 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
Apr 26, 2022
StartActual
Feb 24, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2030
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05346848
Lead sponsor
Institut Bergonié
Collaborators
Bayer
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Feb 24, 2023
Primary completion
Dec 2026 (estimated)
Completion
Feb 2030 (estimated)
Last update
Oct 8, 2026

Study contacts

Paul SARGOS, MD
Contact
p.sargos@bordeaux.unicancer.fr
+33556333333
Simone MATHOULIN-PELISSIER, MD, PhD
Contact
s.mathoulin@bordeaux.unicancer.fr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion